: This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.
Aspirin reduces the risk of type 2 diabetes associated with COVID-19 / Trimarco, Valentina; Izzo, Raffaele; Pacella, Daniela; Manzi, Maria Virginia; Jankauskas, Stanislovas S; Gallo, Paola; Rozza, Francesco; Giugliano, Giuseppe; Spinelli, Alessandra; Esposito, Giovanni; Piccinocchi, Roberto; Piccinocchi, Gaetano; Morisco, Carmine; Lembo, Maria; Santulli, Gaetano; Trimarco, Bruno. - In: NPJ METABOLIC HEALTH AND DISEASE. - ISSN 2948-2828. - 3:1(2025). [10.1038/s44324-025-00072-3]
Aspirin reduces the risk of type 2 diabetes associated with COVID-19
Trimarco, Valentina;Izzo, Raffaele;Pacella, Daniela;Manzi, Maria Virginia;Gallo, Paola;Rozza, Francesco;Giugliano, Giuseppe;Spinelli, Alessandra;Esposito, Giovanni;Piccinocchi, Roberto;Piccinocchi, Gaetano;Morisco, Carmine;Lembo, Maria;Santulli, Gaetano;Trimarco, Bruno
2025
Abstract
: This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
